Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma

27 May 2015

Abstract excerpt

Multiple Myeloma (MM) is a haematologic malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Over the last 10-15 y the introduction of the proteasome-inhibitor bortezomib has improved MM prognosis, however relapse due to bortezomib-resistance is inevitable and the disease, at present, remains incurable. To model bortezomib-resistant MM we generated bortezomib-resistant MM cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25565020
DOI: 10.1080/15384101.2014.998067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myelomaPMID 25565020Read ↗

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read ↗

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read ↗

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma CellsSemantic proximity Read ↗

Clinically relevant pulse-treatment generates bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclaxSemantic proximity Read ↗

NF-kappaB in the pathogenesis and treatment of multiple myeloma.Semantic proximity Read ↗

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.Semantic proximity Read ↗

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaSemantic proximity Read ↗

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsSemantic proximity Read ↗

Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myelomaSemantic proximity Read ↗

Multiple myeloma: lusting for NF-kappaB.Semantic proximity Read ↗

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.